BNC Korea Co. Ltd
BNC Korea Co., Ltd. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj. for temporary improvement of moderate to severe glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity in adults; Juvegel for temporary improvement of moderate to severe nasolabial folds in adults; and Collaple… Read more
BNC Korea Co. Ltd (256840) - Net Assets
Latest net assets as of September 2025: ₩242.51 Billion KRW
Based on the latest financial reports, BNC Korea Co. Ltd (256840) has net assets worth ₩242.51 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩282.67 Billion) and total liabilities (₩40.16 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩242.51 Billion |
| % of Total Assets | 85.79% |
| Annual Growth Rate | 43.41% |
| 5-Year Change | 539.28% |
| 10-Year Change | N/A |
| Growth Volatility | 83.45 |
BNC Korea Co. Ltd - Net Assets Trend (2016–2024)
This chart illustrates how BNC Korea Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BNC Korea Co. Ltd (2016–2024)
The table below shows the annual net assets of BNC Korea Co. Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩236.49 Billion | +12.87% |
| 2023-12-31 | ₩209.53 Billion | +13.91% |
| 2022-12-31 | ₩183.95 Billion | +263.08% |
| 2021-12-31 | ₩50.66 Billion | +36.95% |
| 2020-12-31 | ₩36.99 Billion | +34.14% |
| 2019-12-31 | ₩27.58 Billion | +104.47% |
| 2018-12-31 | ₩13.49 Billion | +1.19% |
| 2017-12-31 | ₩13.33 Billion | +0.80% |
| 2016-12-31 | ₩13.22 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to BNC Korea Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18075101196000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩410.63 Billion | 178.64% |
| Total Equity | ₩229.87 Billion | 100.00% |
BNC Korea Co. Ltd Competitors by Market Cap
The table below lists competitors of BNC Korea Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BIG TECHNOLOGIES LS-10
F:7I8
|
$151.73 Million |
|
Inseego Corp
NASDAQ:INSG
|
$151.74 Million |
|
Wangli Security & Surveillance Product Co. Ltd
SHG:605268
|
$151.74 Million |
|
VRG S.A. ZY -2
F:1NL
|
$151.75 Million |
|
CVRx Inc
NASDAQ:CVRX
|
$151.63 Million |
|
Anhui Provincial Architectural Design and Research Institute Co.Ltd.
SHE:301167
|
$151.56 Million |
|
Sicher Elevator Co. Ltd.
SHE:301056
|
$151.53 Million |
|
Pizza Pizza Royalty Corp
PINK:PZRIF
|
$151.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BNC Korea Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 209,531,906,040 to 229,867,211,300, a change of 20,335,305,260 (9.7%).
- Net income of 13,307,623,100 contributed positively to equity growth.
- Share repurchases of 6,467,233,460 reduced equity.
- New share issuances of 6,467,233,460 increased equity.
- Other factors increased equity by 7,027,682,160.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩13.31 Billion | +5.79% |
| Share Repurchases | ₩6.47 Billion | -2.81% |
| Share Issuances | ₩6.47 Billion | +2.81% |
| Other Changes | ₩7.03 Billion | +3.06% |
| Total Change | ₩- | 9.71% |
Book Value vs Market Value Analysis
This analysis compares BNC Korea Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.17x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.26x to 1.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1788.35 | ₩4040.00 | x |
| 2017-12-31 | ₩1802.71 | ₩4040.00 | x |
| 2018-12-31 | ₩1824.23 | ₩4040.00 | x |
| 2019-12-31 | ₩572.79 | ₩4040.00 | x |
| 2020-12-31 | ₩683.72 | ₩4040.00 | x |
| 2021-12-31 | ₩936.37 | ₩4040.00 | x |
| 2022-12-31 | ₩2785.64 | ₩4040.00 | x |
| 2023-12-31 | ₩3157.31 | ₩4040.00 | x |
| 2024-12-31 | ₩3459.56 | ₩4040.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BNC Korea Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.79%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.91%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.16x
- Recent ROE (5.79%) is above the historical average (-40.89%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -0.09% | 0.00% | 0.00x | 1.13x | ₩-1.33 Billion |
| 2017 | 0.80% | 0.00% | 0.00x | 1.12x | ₩-1.23 Billion |
| 2018 | 1.18% | 0.00% | 0.00x | 1.12x | ₩-1.19 Billion |
| 2019 | -19.59% | -30.57% | 0.36x | 1.80x | ₩-8.16 Billion |
| 2020 | 3.85% | 7.33% | 0.29x | 1.83x | ₩-2.28 Billion |
| 2021 | -347.92% | -698.13% | 0.19x | 2.66x | ₩-181.33 Billion |
| 2022 | -24.30% | -105.68% | 0.18x | 1.26x | ₩-63.10 Billion |
| 2023 | 12.26% | 31.71% | 0.34x | 1.13x | ₩4.73 Billion |
| 2024 | 5.79% | 14.91% | 0.33x | 1.16x | ₩-9.68 Billion |
Industry Comparison
This section compares BNC Korea Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BNC Korea Co. Ltd (256840) | ₩242.51 Billion | -0.09% | 0.17x | $151.72 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |